Ascendis Pharma (NASDAQ: ASND) nets $187.5M from FDA PRV sale

Rhea-AI Filing Summary

Ascendis Pharma A/S has completed the sale of its U.S. Rare Pediatric Disease Priority Review Voucher to an undisclosed buyer for $187.5 million in cash before transaction-related expenses. The Priority Review Voucher was granted by the U.S. Food and Drug Administration following approval of YUVIWEL® (navepegritide) in February 2026.

This Form 6-K is also incorporated by reference into Ascendis Pharma’s existing registration statements on Form S-8 and Form F-3, meaning the information becomes part of those shelf and equity compensation registration documents.

Insights

Biopharma capital markets analyst

Ascendis converts an FDA voucher into $187.5M in cash.

Ascendis Pharma reports completing the sale of a Rare Pediatric Disease Priority Review Voucher for $187.5 million in cash. These vouchers are awarded with certain FDA approvals and can be sold to other drug developers, typically without creating share dilution.

The cash inflow arises from approval of YUVIWEL® (navepegritide) in February 2026, which generated the voucher. The filing does not quantify how this amount compares with Ascendis’s revenue, R&D or cash balances, so the overall balance-sheet effect cannot be assessed from this excerpt alone.

The report also incorporates this information into existing Form S-8 and Form F-3 registration statements, aligning disclosure across Ascendis’s equity compensation and financing documents. Any future capital-raising or share issuance activity under those registrations would reference this updated information.

Key Figures

PRV sale proceeds: $187.5 million cash PRV award timing: February 2026 Form 6-K period: June 2026

3 metrics

PRV sale proceeds $187.5 million cash Sale of Rare Pediatric Disease Priority Review Voucher completed June 17, 2026, before expenses

PRV award timing February 2026 Voucher awarded by FDA upon approval of YUVIWEL (navepegritide)

Form 6-K period June 2026 Report of foreign private issuer for month of June 2026

Key Terms

Rare Pediatric Disease Priority Review Voucher, Form 6-K, Form S-8, Form F-3, +1 more

5 terms

Rare Pediatric Disease Priority Review Voucher regulatory

"sale of its Rare Pediatric Disease Priority Review Voucher (the “PRV”)"

A rare pediatric disease priority review voucher is a transferable regulatory benefit awarded to a company that wins approval for a drug treating a serious but uncommon childhood illness. It works like a “fast-pass” with regulators: the holder can use it to get an accelerated review of a future drug application or sell the voucher to another company, often for a large sum. Investors care because it can speed time to market or generate immediate cash, boosting potential returns and lowering risk on other programs.

Form 6-K regulatory

"This report on Form 6-K shall be deemed to be incorporated by reference"

A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.

Form S-8 regulatory

"incorporated by reference into the registration statements on Form S-8"

A Form S-8 is a U.S. Securities and Exchange Commission registration that lets a public company set aside shares for employee benefit plans and stock-based compensation. Think of it as opening a dedicated account that authorizes the company to issue or reserve stock for workers and directors; it matters to investors because it enables share dilution when those awards are granted or exercised and signals how management is compensated and incentivized.

Form F-3 regulatory

"incorporated by reference into the registration statements on Form S-8 ... and Form F-3"

Form F-3 is a U.S. securities filing that lets eligible foreign companies pre-register and then quickly sell shares or other securities to raise money, because they already meet ongoing reporting and size tests. For investors it signals that the company is up-to-date with regulatory disclosure and has an efficient way to issue new securities — similar to a pre-approved credit line — which can mean faster capital raises but also potential dilution of existing holdings.

YUVIWEL® (navepegritide) medical

"awarded by the U.S. Food and Drug Administration upon approval of YUVIWEL® (navepegritide)"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 06/17/2026 - 04:48 PM Accepted by SEC EDGAR 06/17/2026 - 04:48 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June, 2026

Commission File Number: 001-36815

Ascendis Pharma A/S

(Translation of registrant’s name into English)

Tuborg Boulevard 12

DK-2900 Hellerup

Denmark

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒    Form 40-F ☐

INCORPORATION BY REFERENCE

This report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form S-8 (Registration Numbers 333-203040, 333-210810, 333-211512, 333-213412, 333-214843, 333-216883, 333-228576, 333-254101, 333-261550, 333-270088, 333-277519, 333-281916, 333-285322 and 333-293854) and Form F-3 (Registration Numbers 333-209336 and 333-282196) of Ascendis Pharma A/S (the “Company” or “Ascendis”) (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

On June 17, 2026, the Company completed the previously announced sale of its Rare Pediatric Disease Priority Review Voucher (the “PRV”) to an undisclosed buyer for $187.5 million in cash, before transaction-related expenses. The PRV was awarded by the U.S. Food and Drug Administration upon approval of YUVIWEL^® (navepegritide) in February 2026.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				Ascendis Pharma A/S
Date: June 17, 2026				By:		/s/ Michael Wolff Jensen
						Michael Wolff Jensen
						Executive Vice President, Chief Legal Officer

FAQ

What did Ascendis Pharma (ASND) announce in its June 2026 Form 6-K?

Ascendis Pharma reported completing the sale of its Rare Pediatric Disease Priority Review Voucher for $187.5 million in cash. The voucher came from FDA approval of YUVIWEL (navepegritide) and this information is incorporated into its existing S-8 and F-3 registrations.

How much cash is Ascendis Pharma (ASND) receiving from the PRV sale?

Ascendis Pharma is receiving $187.5 million in cash from selling its Rare Pediatric Disease Priority Review Voucher. This amount is stated before transaction-related expenses, so the final net proceeds to the company will be somewhat lower after costs associated with the sale.

What is the source of Ascendis Pharma’s Rare Pediatric Disease Priority Review Voucher?

The Rare Pediatric Disease Priority Review Voucher was awarded by the U.S. Food and Drug Administration after approval of YUVIWEL (navepegritide) in February 2026. FDA approval of this therapy triggered the voucher grant, which Ascendis subsequently sold to an undisclosed buyer.

Who bought Ascendis Pharma’s Priority Review Voucher and is the buyer named?

The buyer of Ascendis Pharma’s Rare Pediatric Disease Priority Review Voucher is not identified. The Form 6-K states the voucher was sold to an “undisclosed buyer,” so no information is provided about the purchaser or their intended use of the voucher.

How does this Form 6-K affect Ascendis Pharma’s existing registration statements?

This Form 6-K is incorporated by reference into Ascendis Pharma’s Form S-8 and Form F-3 registration statements. That means the disclosed PRV sale and related information become part of those filings, updating the disclosure base for equity compensation and potential future offerings.

What product is linked to the FDA voucher mentioned by Ascendis Pharma (ASND)?

The FDA voucher is linked to YUVIWEL (navepegritide), which received approval in February 2026. That approval led the U.S. Food and Drug Administration to grant Ascendis a Rare Pediatric Disease Priority Review Voucher that the company later sold for $187.5 million in cash.